Covington Aids AstraZeneca In $1.3B Ardea Biotech Buy
It is the British drugmaker's biggest acquisition — and its first of more than $1 billion — since 2007, when it bought MedImmune Inc. for $15.2 billion. The $32 per-share purchase price represents a 54 percent premium over Ardea's stock price at Friday's close.
San Diego-based Ardea's most clinically advanced drug treats high...
To view the full article, register now.